funding for travel or speaker honoraria : ( 1 ) istanbul ms days , novartis pharmaceuticals , speaker honoraria payment to mayo clinic . no personal compensation .
( 2 ) invited professor program , biogen - boston , speaker honoraria payment to mayo clinic . no personal compensation .
other activities : grant review for the national multiple sclerosis society . research support , commercial entities : dr .
orhun h. kantarci receives research support from the european regional development fund ( fnusaicrc cz.1.05/1.1.00/02.0123 ) , the national multiple sclerosis society , and has given a scientific presentation at a meeting supported by teva pharmaceuticals but has received no personal fees or personal compensation for this activity ( all compensation for consulting activities paid directly to mayo clinic ) nor has spoken about the specific medications involving this company .
kejal kantarci ( spouse ) serves on the data safety monitoring board of takeda global research and development center , inc . , and the data monitoring boards of pfizer inc . and janssen alzheimer immunotherapy and is funded by the nih ( r01 ag040042 [ pi ] , r21 ns066147 [ pi ] , p50 ag44170/project 2 [ pi ] , p50 ag16574/project 1 [ pi ] , r01 ag11378 [ co - i ] , u19 ag10483 [ co - i ] u01 ag042791 [ co - i ] ) and minnesota partnership for biotechnology and medical genomics ( po03590201 [ pi ] ) .
kejal kantarci serves on the data safety monitoring board of takeda global research and development center , inc . , and the data monitoring boards of pfizer inc .
and janssen alzheimer immunotherapy and is funded by the nih ( r01 ag040042 [ pi ] , r21 ns066147 [ pi ] , p50 ag44170/project 2 [ pi ] , p50 ag16574/project 1 [ pi ] , r01 ag11378 [ co - i ] , u19 ag10483 [ co - i ] u01 ag042791 [ co - i ] ) and minnesota partnership for biotechnology and medical genomics ( po03590201 [ pi ] )
kejal kantarci serves on the data safety monitoring board of takeda global research and development center , inc .
janssen alzheimer immunotherapy and is funded by the nih ( r01 ag040042 [ pi ] , r21 ns066147 [ pi ] , p50 ag44170/project 2 [ pi ] , p50 ag16574/project 1 [ pi ] , r01 ag11378 [ co - i ] , u19 ag10483 [ co - i ] u01 ag042791 [ co - i ] ) and minnesota partnership for biotechnology and medical genomics ( po03590201 [ pi ] ) .
research support , foundations and societies : 20062009 multiple sclerosis society for support in multiple sclerosis research unrelated to this publication ; 20082009 mayo foundation cr20 award for support in multiple sclerosis research unrelated to this publication ; 20092011 hilton foundation support in multiple sclerosis research unrelated to this publication .
 before the genomics technology revolution allowed us to do genome - wide science , genetics research relied on our limited knowledge about a subject to generate hypothesis and candidate genes to study . despite the level of naivet , several associations with susceptibility to a complex disease such as multiple sclerosis ( ms ) were discovered . of these , 
 hla - drb1 and il7r1 stand out as being confirmed and refined early by the genome - wide association studies ( gwas ) that followed.2 despite the expense and gargantuan efforts , these gwas have successfully led to the discovery of more than 100 additional genes , albeit with smaller effect sizes , that contribute to ms susceptibility.3 this list keeps growing , but it comes with no surprise that most of these genes identified the immune system as one large candidate for ms susceptibility . 
STUDY FUNDING
DISCLOSURE